Table 1. High frequency of TP53... | American Society of Hematology

Table 1.

High frequency of TP53 mutation, del(17p), and del(18p) in our cohort compared with published cohorts

Genetic abnormality	Current study (N = 9)	Comparison with published cohorts
		Untreated/unspecified										Treated/relapsed						CLL phase of RT
		Campo (N = 506)		CLL8 trial (N = 635)*		ERIC (N = 827)*		Chaganti (N = 228)		Wu (N = 538)		ERIC (N = 1562)*		Chaganti (N = 60)		Wu (N = 59)		Bertoni (N = 28)
	%	%	P	%	P	%	P	%	P	%	P	%	P	%	P	%	P	%	P
SF3B1	22	8	.11	18	.77	3	6.90e-04†			21	.93	16	.62
TP53	89	5	<2.2e-16†	11	3.40e-12†	4	<2.2e-16†			7	<2.2e-16†	13	2.40e-11†			29	4.90e-04†
del(17p)	89	4	<2.2e-16†	8	2.54e-16†	3	<2.2e-16†	4	<2.2e-16†	6	<2.2e-16†	10	1.76e-14†	13	5.49e-07†	24	9.94e-05†	32	.002962†
del(18p)	56	2	<2.2e-16†					4	1.20e-10†	2	<2.2e-16†			3	1.30e-06†	7	5.80e-05†	11	.0045†
del(13q)	56	50	.74	57	.94	48	.66	55	.9862	47	.63	33	.15	50	.76	22	.034‡	32	.21
8q gain (MYC)	33	2	4.40e-08†					4	3.00e-05†	3	3.50e-07†			5	.005†
del(8p)	33	1	5.77e-12†					4	3.03e-05†	4	6.39e-06†			5	.0049†			11	.11
del(9p) (CDKN2A)	33	0	<2.2e-16†							0	<2.2e-16†			0	4.80e-06†
Tri12	33	14	.11	12	.052	13	.066	14	.1095	13	.084	17	.21	8	.029‡	7	.015‡	29	.79
del(6q21)	22	2	1.40e-04†					2	5.00e-04†	3	.0027†			5	.063	7	.13
del(14q)	22	5	.029‡

Genetic abnormality	Current study (N = 9)	Comparison with published cohorts
		Untreated/unspecified										Treated/relapsed						CLL phase of RT
		Campo (N = 506)		CLL8 trial (N = 635)*		ERIC (N = 827)*		Chaganti (N = 228)		Wu (N = 538)		ERIC (N = 1562)*		Chaganti (N = 60)		Wu (N = 59)		Bertoni (N = 28)
	%	%	P	%	P	%	P	%	P	%	P	%	P	%	P	%	P	%	P
SF3B1	22	8	.11	18	.77	3	6.90e-04†			21	.93	16	.62
TP53	89	5	<2.2e-16†	11	3.40e-12†	4	<2.2e-16†			7	<2.2e-16†	13	2.40e-11†			29	4.90e-04†
del(17p)	89	4	<2.2e-16†	8	2.54e-16†	3	<2.2e-16†	4	<2.2e-16†	6	<2.2e-16†	10	1.76e-14†	13	5.49e-07†	24	9.94e-05†	32	.002962†
del(18p)	56	2	<2.2e-16†					4	1.20e-10†	2	<2.2e-16†			3	1.30e-06†	7	5.80e-05†	11	.0045†
del(13q)	56	50	.74	57	.94	48	.66	55	.9862	47	.63	33	.15	50	.76	22	.034‡	32	.21
8q gain (MYC)	33	2	4.40e-08†					4	3.00e-05†	3	3.50e-07†			5	.005†
del(8p)	33	1	5.77e-12†					4	3.03e-05†	4	6.39e-06†			5	.0049†			11	.11
del(9p) (CDKN2A)	33	0	<2.2e-16†							0	<2.2e-16†			0	4.80e-06†
Tri12	33	14	.11	12	.052	13	.066	14	.1095	13	.084	17	.21	8	.029‡	7	.015‡	29	.79
del(6q21)	22	2	1.40e-04†					2	5.00e-04†	3	.0027†			5	.063	7	.13
del(14q)	22	5	.029‡

Tri, trisomy.

Total number of patient cases studied varies depending on specific genetic abnormality. Blank boxes indicate data unavailable.

P < .005; ‡P < .05.